Israel - anglès - Ministry of Health

astrazeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapyfaslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy;or* with disease progression on endocrine therapy.combination therapy faslodex is indicated for the treatment of:- hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.- hr- positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - fulvestrant, quantity: 50 mg/ml - injection, solution - excipient ingredients: ethanol; benzyl alcohol; benzyl benzoate; castor oil - faslodex is indicated for the treatment of postmenopausal women with:,? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.,? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

Panamà - anglès - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sandoz gmbh - fulvestrant - fulvestrant....250 mg.

Panamà - anglès - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios laprin, s.a. - fulvestrant - fulvestrant....50,00 mg

Singapur - anglès - HSA (Health Sciences Authority)

sandoz singapore pte. ltd. - fulvestrant - injection, solution - fulvestrant 250mg/5ml

Panamà - anglès - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

dr. reddy's laboratories (uk) limited - fulvestrant - fulvestrant....250,00 mg

Panamà - anglès - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

ever valinject gmbh - fulvestrant - fulvestrant....50,00 mg

Estats Units - anglès - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - fulvestrant 50 mg in 1 ml - monotherapy faslodex is indicated for the treatment of: combination therapy faslodex is indicated for the treatment of: faslodex is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with faslodex [see adverse reactions (6.2)]. risk summary based on findings from animal studies and its mechanism of action, faslodex can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data] . advise pregnant women of the potential risk to a fetus. the estimated backg

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

accord healthcare limited - fulvestrant - solution for injection in pre-filled syringe - 250mg millilitre - anti-estrogens

Canadà - anglès - Health Canada

teva canada limited - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents